)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Viatris
Viatris (VTRS) investor relations material
Viatris 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Business overview and recent performance
Operates as three businesses: global generics, established brands, and emerging innovative brands, with $14.1B revenue and $2.2B free cash flow in the last 12 months, serving over 1 billion people annually in 165 countries.
Achieved strong commercial execution in 2025, advancing five Phase 3 pipeline assets and delivering robust financial results.
Returned over $1B to shareholders via dividends and buybacks, including quarterly dividends in 2025.
Completed 60 regional business development deals, including the acquisition of Aculys Pharma in Japan, and prioritized Japan for strategic growth.
Substantially completed remediation at Indore facility and conducted an enterprise-wide strategic review to drive efficiency and future readiness.
Strategic initiatives and growth outlook
Anticipates high-value launches in 2026, including sotagliflozin, phentolamine, fast-acting meloxicam, Spidifen, pitolisant, and Effexor GAD in key geographies.
Enterprise-wide strategic review expected to yield substantial savings and reinvestment opportunities starting in 2026, with benefits extending through 2028.
Plans to use significant 2026 cash flow for shareholder returns and accretive business development, especially in the U.S. and globally.
Pipeline milestones and new launches are expected to drive sustainable top- and bottom-line growth from 2026 onward.
Focused on mid-single digit revenue growth, moving beyond prior periods of revenue and EBITDA decline.
Pipeline and product opportunities
Five positive Phase 3 results in 2025, with anticipated approvals in 2026; Spidifen launched in Japan, pitolisant filed for narcolepsy and sleep apnea.
Cenerimod and selatogrel progressing in Phase 3, with full enrollment expected this year; cenerimod targets SLE and lupus nephritis, addressing significant unmet needs.
Fast-acting meloxicam positioned as a non-opioid acute pain solution, targeting large U.S. market with strong data and 3–5 years of exclusivity, potentially longer with additional patents.
Selatogrel seen as a paradigm shift for acute MI, leveraging company expertise in rescue medicines and global cardiovascular infrastructure.
Additional launches include Effexor GAD and low-dose estrogen patch in Japan, and a presbyopia eye care product with anticipated approval this year.
Indore facility reinspection timeline
Impact of $2.9B goodwill impairment?
Selatogrel, Cenerimod: long-term growth outlook
What specific criteria guide U.S. BD asset selection?
Quantify enterprise review savings and reinvestment ratio.
Selatogrel: Key risks for market adoption?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Viatris earnings date
Q4 202526 Feb, 2026
Viatris
Next Viatris earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
The company provides medicines used to treat a range of therapeutic areas around the world, including cardiovascular, anti-virals, antibiotics, central nervous system, dermatologic, gastroenterology, immunosuppressant, oncology and pain, respiratory, and women's health products. Its treatments are available through its different medicines. The company was formerly known as Mylan N.V. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage